NEOK Bio vs Clasp Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.
About
NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.
Clasp Therapeutics develops tumor-specific T cell engagers targeting mutant p53 and other cancer driver mutation peptides presented by HLA molecules, enabling precise solid tumor immunotherapy.
About
Clasp Therapeutics is a clinical-stage immuno-oncology company developing precision T cell engagers (TCEs) that direct the immune system to destroy solid tumors harboring common oncogenic driver mutations. Unlike first-generation TCEs that target proteins shared between tumor and healthy cells, Clasp''s bispecific antibodies recognize tumor-specific peptide-HLA complexes — molecular fingerprints unique to cancer cells created by mutated proteins.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.